Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy

NCT06309459 is registered in ClinicalTrials.gov with Kahramanmaras Sutcu Imam University as lead sponsor.

NCT NCT06309459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06309459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Factors and Response to Neoadjuvant Chemotherapy
Lead sponsor
Kahramanmaras Sutcu Imam University
Phase
Observational
Overall status
Completed
Start date
August 1, 2018
Completion date
May 1, 2023
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carbonic anhydrase ix, triple negative breast cancer